We are live on
!
Find out more
1C
1623 Capital Portfolio holdings
AUM
$173M
1-Year Est. Return
17.08%
This Fund
S&P 500
This Quarter
Est. Return
+1.22%
1 Year Est. Return
+17.08%
3 Year Est. Return
+11.9%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$4.65M
(-1.8%)
Cap. Flow
-$2.77M
Cap. Flow
% of AUM
-1.08%
Top 10 Holdings %
Top 10 Hldgs %
42.52%
Holding
81
New
9
Increased
13
Reduced
2
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Affirm
AFRM
|
+$879K |
| 2 |
OLO
Olo Inc
OLO
|
+$686K |
| 3 |
Celsius Holdings
CELH
|
+$678K |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$656K |
| 5 |
Etsy
ETSY
|
+$406K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$5.96M |
| 2 |
IPG Photonics
IPGP
|
+$750K |
| 3 |
NVIDIA
NVDA
|
+$603K |
| 4 |
TSMC
TSM
|
+$454K |
| 5 |
nLIGHT
LASR
|
+$436K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.39% |
| 2 | Consumer Discretionary | 12.95% |
| 3 | Financials | 12.03% |
| 4 | Healthcare | 11.19% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Kodiak Sciences
KOD
$2.6B
| $504K | 0.2% |
5,256
| – | – |
|
|
52
nLIGHT
LASR
$3.88B
| $499K | 0.2% |
17,700
-14,643
| -45% | -$436K |
|
53
Cardlytics
CDLX
$21.7M
| $467K | 0.18% |
557
| – | – |
|
54
Penumbra
PEN
$12.7B
| $467K | 0.18% |
1,751
| – | – |
|
55
PayPal
PYPL
$48.9B
| $462K | 0.18% |
1,777
| – | – |
|
56
Ultragenyx Pharmaceutical
RARE
$2.45B
| $422K | 0.16% |
4,677
+900
| +24% | +$81.3K |
|
57
Unity
U
$13.8B
| $404K | 0.16% |
3,203
| – | – |
|
58
BioMarin Pharmaceuticals
BMRN
$11.6B
| $372K | 0.15% |
4,814
| – | – |
|
59
Palantir
PLTR
$295B
| $329K | 0.13% |
13,691
| – | – |
|
|
ISEE
60
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $325K | 0.13% |
+20,000
| New | +$218K |
|
61
C3.ai
AI
$1.43B
| $324K | 0.13% |
+6,986
| New | +$355K |
|
62
Cognex
CGNX
$10.9B
| $317K | 0.12% |
3,948
| – | – |
|
63
Globus Medical
GMED
$10.7B
| $315K | 0.12% |
4,114
| – | – |
|
64
Intellia Therapeutics
NTLA
$1.49B
| $309K | 0.12% |
2,300
-941
| -29% | -$142K |
|
65
Vuzix
VUZI
$194M
| $289K | 0.11% |
+27,631
| New | +$370K |
|
|
NVTA
66
DELISTED
Invitae Corporation
NVTA
| $288K | 0.11% |
10,135
| – | – |
|
|
NARI
67
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $285K | 0.11% |
3,517
| – | – |
|
68
Roblox
RBLX
$25.4B
| $284K | 0.11% |
3,762
| – | – |
|
69
Novavax
NVAX
$1.2B
| $227K | 0.09% |
+1,095
| New | +$241K |
|
70
Zymeworks
ZYME
$1.61B
| $224K | 0.09% |
+7,724
| New | +$257K |
|
71
Natera
NTRA
$38.3B
| $213K | 0.08% |
+1,908
| New | +$219K |
|
|
FIRY
72
Firy Inc
FIRY
$148M
| $154K | 0.06% |
+782
| New | +$202K |
|
|
TECX
73
Tectonic Therapeutic
TECX
$529M
| $103K | 0.04% |
1,540
+583
| +61% | +$47.8K |
|
74
PolyPid
PYPD
$82.3M
| $90K | 0.04% |
388
| – | – |
|
|
75
Illumina
ILMN
$31B
| – | – |
-12,953
| Closed | -$5.96M |
|
Similar funds
GA
CBC
WWP
IGWM
HWMA
RA
SWM
SVI
1623 Capital's Q3 2021 Portfolio in Review
As of Q3 2021, 1623 Capital held 81 positions worth $256M, down 1.8% from $261M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
1623 Capital's Q3 2021 filing shows 9 new, 13 increased, 2 reduced and 7 closed positions. Its largest new stake was Affirm: 11,000 shares worth $1.31M. The largest sale was Illumina, an estimated $5.96M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Consumer Discretionary and Financials.
- 1623 Capital's largest Q3 2021 buy was Affirm: 11,000 shares worth $1.31M.
- 1623 Capital added most to Olo Inc in Q3 2021, an estimated $686K increase.
- 1623 Capital's biggest Q3 2021 reduction was nLIGHT, cutting an estimated $436K.
- 1623 Capital fully exited Illumina in Q3 2021, selling an estimated $5.96M.
- 1623 Capital's ten largest holdings make up 43% of its $256M portfolio in Q3 2021.
- 1623 Capital opened 9 new positions and closed 7 in Q3 2021.
- 1623 Capital's portfolio value fell 1.8% quarter-over-quarter to $256M.
Based on 1623 Capital's 13F filing for Q3 2021, filed 12 Nov 2021.